Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative 4D-DIA LC–MS/MS analysis of TPM3P9 RNA pulldown proteins in primary breast cancer cells (PBCs#2/#3/#5) and bone-metastatic breast cancer cells (BMBCs#2/#3/#5)

ABSTRACT: This project aims to identify and quantify TPM3P9 RNA-associated proteins in primary breast cancer cells (PBCs#2/#3/#5) and bone-metastatic breast cancer cells (BMBCs#2/#3/#5) using 4D-DIA LC–MS/MS. RNA pulldown assays were performed with tRSA-based TPM3P9 RNA to capture interacting proteins, which were subsequently analyzed by 4D-DIA-based quantitative proteomics. The objective is to elucidate the translational regulation mechanism of osteolysin in bone-metastatic breast cancer cells and to identify specific RNA-binding proteins involved in osteolysin translation.

ORGANISM(S): Homo Sapiens

SUBMITTER: Jun Li

PROVIDER: PXD070203 | iProX | Fri Oct 31 00:00:00 GMT 2025

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

LC-MS/MS analysis of two breast cancer cell lines, MDA-MB-231 and SCP2 cells

Project description:Bone is the most common metastasis site in patients with breast cancer, and approximately up to 80% of patients with advanced breast cancer (BC) develop bone metastasis (BM), which leads to a worse prognosis with a median survival of 16 months and skeletal-related events (SREs), including severe bone pain, pathological fracture, hypercalcemia and lethal complications. Using quantitative proteomics mass-spectrometry (MS) analysis of low bone-metastatic BC cells (MDA-MB-231) and high bone-metastatic BC cells (SCP2), we identified an unreported breast cancer (BC) cells–secreted microprotein, LINC00263-P, encoded by lincRNA LINC00263 and clinically associated with BC bone-tropism.

2025-01-06 | PXD059452 |

LC-MS/MS analysis of conditioned medium from primary breast cancer cells (PBCs#2/#3/#5) and bone-metastatic breast cancer cells (BMBCs#2/#3/#5)

Project description:Bone is the most common metastasis site in patients with breast cancer, and approximately up to 80% of patients with advanced breast cancer (BC) develop bone metastasis (BM), which leads to a worse prognosis with a median survival of 16 months and skeletal-related events (SREs), including severe bone pain, pathological fracture, hypercalcemia and lethal complications. Using quantitative proteomics mass-spectrometry (MS) analysis of the secretome from patient-derived primary BC cells (PBCs) and bone-metastatic BC cells (BMBCs), we identified an unreported breast cancer (BC) cells–secreted microprotein, osteolysin, encoded by tropomyosin 3 pseudogene 9 (TPM3P9) and clinically associated with BC bone-tropism.

2024-07-05 | PXD053732 |

Towards understanding breast cancer mechanisms to metastasize

Project description:How organ-specific metastatic traits accumulate in primary tumors remains unknown. We identified a role of the primary tumor stroma in selecting breast cancer cells that are primed for metastasis in the bone. A fibroblast-rich stroma in breast tumors creates a microenvironment that is similar to that of bone metastases in its abundance of the cytokines CXCL12 and IGF1. Heterogeneous breast cancer cell populations growing in such mesenchymal environment evolve towards a preponderance of clones that thrive on CXCL12 and IGF1. Fibroblast-driven selection of bone metastatic clones in mammary tumors is suppressed by CXCL12 and IGF1 receptor inhibition. Thus, a fibroblast-rich stroma in breast tumors can pre-select bone metastatic seeds, promoting the evolution of metastatic traits and the interplay between a primary tumor and its distant metastases. Affymetrix U133 Plus2 arrays were hybridized according to the manufacturer's procedure using RNA extracted from 47 primary breast tumors. Specific gene sets were evaluated in this cohort.

2013-11-01 | E-GEOD-47389 | biostudies-arrayexpress

ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone

Project description:Bone is the primary site of breast cancer metastasis and complications associated with bone metastases can lead to a significantly decreased quality of life in these patients. Thus, it is essential to gain a better understanding of the molecular mechanisms that underlie the emergence and growth of breast cancer skeletal metastases. Methods: To search for novel molecular mediators that influence breast cancer bone metastasis, we generated gene expression profiles from laser capture micro-dissected trephine biopsies of both breast cancer bone metastases and primary breast tumors that metastasized to bone. Bioinformatics analysis identified genes that are differentially expressed in breast cancer bone metastases compared to primary mammary tumors. Results: ABCC5, an ATP-dependent transporter, was found to be overexpressed in breast cancer osseous metastases relative to primary mammary tumors. In addition, ABCC5 was significantly up-regulated in human and mouse breast cancer cell lines with high bone-metastatic potential. Stable knockdown of ABCC5 significant reduced bone metastatic burden and osteolytic bone destruction in mice. The decrease in osteolysis was further associated with diminished osteoclast numbers. Conclusions: Our data, for the first time, suggests that ABCC5 functions as a mediator of breast cancer skeletal metastasis. ABCC5 expression in breast cancer cells is important for the efficient bone resorption mediated by osteoclasts. Hence, ABCC5 may be a potential therapeutic target for breast cancer bone metastasis. primary breast tumors vs. bone trephine biopsies

2012-11-09 | E-GEOD-39494 | biostudies-arrayexpress

Towards understanding breast cancer mechanisms to metastasize

2013-11-01 | GSE47389 | GEO

ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone

2012-11-09 | GSE39494 | GEO

Expression data of extracellular vesicles from bone metastatic breast cancer cell line

Project description:Bone metastasis is an incurable complication of breast cancer. In advanced stages, patients with estrogen-positive tumors experience significantly higher incidence of bone metastasis compared to estrogen-negative patients. To investigate how estrogen-positive breast cancer cells communicate with bone microenvironmental cells, extracellular vesicles from bone metastatic MCF7BoM2 were purified and analyzed. We used GeneChip miRNA 4.1 Array to detail the miRNA expression in the extracellular vesicles from the bone metastatic MCF7BoM2 and its parental cell line MCF7, and identified the dysregulated miRNAs.

2021-06-04 | GSE176105 | GEO

Identification of circRNA Expression Signatures for breast cancer metastasis

Project description:To identify breast cancer metastasis-relevant circRNAs, we assessed the expression profiles of circRNAs in parental MDA-MB-231 (231-PAR) cells, isogenic brain metastatic cells (231-BM6), lung metastatic cells (LM2) and bone metastatic cells (1833), which were isolated from brain, lung or bone-seeking 231-PAR cells

2019-03-01 | GSE111504 | GEO

Organ-specific tropism and adaptation after metastasis of ER+ breast cancers

Project description:Patients diagnosed with estrogen receptor (ER) positive breast cancer have a prolonged risk of distal metastatic recurrence to vital organs. Metastatic disease is incurable at present due to the development of treatment resistant cell populations. Here we used single-cell RNA sequencing to evaluate the transcriptome heterogeneity of ER+ breast cancer patient-derived xenografts (PDX) tropic for three common breast cancer metastatic sites – bone, brain, and liver – compared to primary tumors grown in the mammary fat pad. Metastatic cell populations at each location were phenotypically distinct from primary tumor cells with unique transcriptional programs indicative of signaling programs driven by specific transcription factors. Cells that metastasized to brain and liver tissue adopted gene expression programs indicative of the target organ microenvironments. Discerning the organ-specific phenotypic adaptations of metastatic ER+ breast cancer cells may help tailor appropriate therapies for individual patients and to each metastatic site.

2020-05-09 | GSE131007 | GEO

AR Expression in Breast Cancer CTCs Associates with Bone Metastases

Project description:Molecular drivers underlying bone metastases in human cancer are not well understood, in part due to constraints in bone tissue sampling. Here, we undertook RNA sequencing of circulating tumor cells (CTCs) obtained from blood samples of women with metastatic estrogen receptor (ER)+ breast cancer, comparing cases with progression in bone versus visceral organs. Among the activated cellular pathways in CTCs from bone-predominant breast cancer is Androgen Receptor (AR) signaling. AR gene expression is evident, as is its constitutively active splicing variant AR-v7. AR expression within CTCs is correlated with the duration of treatment with aromatase inhibitors, suggesting that it may contribute to acquired resistance to anti-estrogen therapy. In an established breast cancer xenograft model, a bone-tropic derivative displays increased AR expression, whose genetic or pharmacologic suppression reduces metastases to bone but not to lungs. Together, these observations identify AR signaling in CTCs from women with bone-predominant ER+ breast cancer, and provide a rationale for testing androgen inhibitors in this subset of patients.

2018-02-19 | GSE86978 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data